Chernov M V, Ramana C V, Adler V V, Stark G R
Department of Molecular Biology, Lerner Research Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2284-9. doi: 10.1073/pnas.95.5.2284.
Treatment of mouse or human cells with the protein kinase C (PKC) inhibitors H7 or bisindolylmaleimide I induced an increase in the lifetime of p53, leading to its accumulation. In inhibitor-treated cells, p53 translocated to the nuclei and bound to DNA but was not competent to induce transcription. However, transactivation could be induced by subsequent DNA damage. Phorbol ester, a potent activator of PKC, significantly inhibited the accumulation of p53 after DNA damage. Therefore, constitutive PKC-dependent phosphorylation of p53 itself, or of a protein that interacts with p53, is required for the rapid degradation of p53 in untreated cells. Furthermore, an increase in the lifetime of p53 is not accompanied necessarily by its activation. Treatment with the PKC inhibitors decreased the overall level of p53 phosphorylation but led to the appearance of a phosphopeptide not seen in tryptic digests of p53 from untreated cells. Therefore, the lifetime and activities of p53 are likely to be regulated by distinct alterations of the phosphorylation pattern of p53, probably caused by the actions of different kinases.
用蛋白激酶C(PKC)抑制剂H7或双吲哚马来酰亚胺I处理小鼠或人类细胞,会导致p53寿命延长,进而使其积累。在抑制剂处理的细胞中,p53易位至细胞核并与DNA结合,但无能力诱导转录。然而,后续的DNA损伤可诱导反式激活。佛波酯是一种有效的PKC激活剂,可显著抑制DNA损伤后p53的积累。因此,在未处理的细胞中,p53自身或与p53相互作用的蛋白质的组成型PKC依赖性磷酸化是p53快速降解所必需的。此外,p53寿命的延长不一定伴随着其激活。用PKC抑制剂处理会降低p53磷酸化的总体水平,但会导致出现一种在未处理细胞的p53胰蛋白酶消化物中未见的磷酸肽。因此,p53的寿命和活性可能受p53磷酸化模式的不同改变调节,这可能是由不同激酶的作用引起的。